Single-cell genome sequencing is a powerful technique that enables the analysis of full genetic material from individual cells, allowing researchers to highlight genetic variations, mutation and cellular inequality that which wholesale sequencing is often missed. The market for this technique is growing rapidly, due to the increasing demand for accurate medicine, cancer research, and immune profiles, technological progress in microfluidics, the next generation sequencing, and AI-operated data analysis, as well as making single-cell workflow more scalable, cost-purpose and clinically relevant.
Key Growth Drivers and Opportunities
rising Demand for Accurate and Personalized Medicine: Increasing demand for accurate and personalized drugs is a major driver of single-cell genome sequencing market, as this technique allows for detailed genetic analysis at the individual cell level-important to identify drugs goals and treatment reactions. Especially by enabling accurate diagnostics and sequential therapy in oncology, immunology and neurology, the single-cell sequencing supports more effective, changes towards patient-specific medical interventions, fueling its adoption in research and clinical settings.
Challenges
Despite its rapid growth, the single-cell genome sequencing faces several borders in the market, including the high cost of equipment and reagents, complex sample preparation protocols, and large-scale, data interpretations due to the noise dataset include challenges. Additionally, limited standardization in platforms and analytical devices may obstruct fertility and scalability, especially in clinical applications. These factors prohibit adoption widely, especially in low-resources settings and small research institutes.
Innovation and Expansion
Roche and Broad Clinical Labs Collaborate to Advance the Rollout of Next-Gen SBX Sequencing
In May 2025, Roche and Broad Clinical Labs established a collaborative partnership to create and test innovative applications utilizing Roche’s recently introduced Sequencing by Expansion (SBX) next-generation sequencing (NGS) technology.
The goal of this partnership is to use SBX technology to revolutionize biomedical research and clinical genomics. Additionally, it will seek to make SBX technology a standard product for the research community at Broad Clinical Labs in terms of quick, scalable sequencing.
Ultima Genomics’ UG 100TM Platform Partnership Increases Access to Inexpensive DNA Sequencing Worldwide
In February 2025, The UG100TM next-generation sequencing (NGS) platform’s creator, Ultima Genomics, Inc., announced several new collaborations with top genomic services providers, expanding access to high-quality, reasonably priced DNA sequencing worldwide. In order to facilitate single cell sequencing, spatial transcriptomics, proteomics, whole genome sequencing, and other applications, this international network of renowned service providers will deliver industry-leading DNA sequencing services using the UG 100.
The Ontario Institute of Cancer Research, Novogene, Psomagen, Eurofins, and Broad Clinical Labs are among the top-tier companies that were revealed today. These partners join the University of Minnesota Genomics Center, Macrogen, and Inocras as current Ultima Genomics service provider partners.
Inventive Sparks, Expanding Markets
Key players operating in the single-cell genome sequencing include ThermoFisher Scientific, Inc., Illumina, Bio-Rad, BD, Pacific Biosciences of California, Inc., QIAGEN, 10X Genomics, Inc., BGI, Novogene Co. Ltd., NuGEN Technologies, Inc., Takara Bio, Inc., F Hoffmann-La Roche Ltd., Oxford Nanopore Technologies, Fludigim, and Agilent Technologies Inc.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.